

**Subject** Controlled Substance Schedules Modifications

**Authors** Howard

**Analyst** Jeff Diebel

**Date** March 4, 2020

## Overview

This bill contains a variety of revisions to the controlled substance schedules proposed by the Board of Pharmacy.

## Summary

Section	Description
1	<b>Schedule I.</b> Adds substances to Schedule I of the statutory controlled substances schedules. The new drugs include opioid and fentanyl analogs, synthetic cannabinoids, and some benzodiazepines (related to Valium). (Schedule I drugs are those that have a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision.)
2	<b>Schedule II.</b> Adds the FDA-approved medication dronabinol to Schedule II, which is consistent with current federal drug schedules. Dronabinol is synthetic THC that has been approved for loss of appetite and weight loss in patients with AIDS; and for nausea and vomiting associated with cancer chemotherapy. (Schedule II drugs are those that have a high potential for abuse, currently accepted medical uses, and that abuse may lead to severe psychological or physical dependence.)
3	<b>Schedule V.</b> Adds gabapentin, which is used to treat seizures and pain, to Schedule V. Also adds epidiolex—which contains CBD—to Schedule V. (Schedule V drugs are those that have a lower potential for abuse than drugs on Schedule IV, currently accepted medical uses, and abuse may lead to limited physical or psychological dependence.)



**MN HOUSE  
RESEARCH**

*Minnesota House Research Department provides nonpartisan legislative, legal, and information services to the Minnesota House of Representatives. This document can be made available in alternative formats.*

[www.house.mn/hrd](http://www.house.mn/hrd) | 651-296-6753 | 600 State Office Building | St. Paul, MN 55155